Jordan Berlin
Vanderbilt University
CancerPathologyOncologyColorectal cancerMedicine
What is this?
Publications 369
#1S. Lindsey Davis (CU: University of Colorado Boulder)H-Index: 6
#2Dana Backlund Cardin (Vandy: Vanderbilt University)H-Index: 12
Last. Steven J. Cohen (Abington Memorial Hospital)H-Index: 34
view all 11 authors...
Vantictumab is a fully human monoclonal antibody that inhibits Wnt pathway signaling through binding FZD1, 2, 5, 7, and 8 receptors. This phase Ib study evaluated vantictumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma. Patients received vantictumab at escalating doses in combination with standard dosing of nab-paclitaxel and gemcitabine according to a 3 + 3 design. A total of 31 patients were treated in 5 dosing cohorts. Fra...
1 CitationsSource
#1Marc T. Roth (Vandy: Vanderbilt University)H-Index: 1
#2Dana Backlund Cardin (Vandy: Vanderbilt University)H-Index: 12
Last. Jordan Berlin (Vandy: Vanderbilt University)H-Index: 52
view all 9 authors...
LESSONS LEARNED This trial evaluating a novel plant extract, PBI-05204, did not meet its primary endpoint of overall survival but did show signals of efficacy in heavily pretreated mPDA. PBI-05204 was generally well tolerated, with the most common side effects related to treatment being vomiting (23.7%), nausea (18.4%), decreased appetite (18.4%), and diarrhea (15.8%). Additional trials are needed to explore the role of PBI-05204 in cancer treatment. BACKGROUND Survival for metastatic pancreatic...
#1Shivaani Kummar (Stanford University)H-Index: 40
#2Cornelis M. van Tilburg (DKFZ: German Cancer Research Center)H-Index: 7
Last. Ulrik LassenH-Index: 30
view all 19 authors...
#1Michele Reni (UniSR: Vita-Salute San Raffaele University)H-Index: 49
#2Hanno Riess (Charité)H-Index: 37
Last. Warren S. Brenner (Boca Raton Regional Hospital)H-Index: 1
view all 18 authors...
#1Alexander Drilon (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 34
#2Anna F. Farago (Harvard University)H-Index: 25
Last. Makoto TaharaH-Index: 12
view all 17 authors...
3610Background: The highly selective TRK inhibitor larotrectinib is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ...
#2Michael K. Gibson (Vandy: Vanderbilt University)H-Index: 2
view all 5 authors...
#1Michele Reni (UniSR: Vita-Salute San Raffaele University)H-Index: 49
#2Hanno Riess (Charité)H-Index: 37
Last. Scot D. Dowden (TBCC: Tom Baker Cancer Centre)H-Index: 5
view all 17 authors...
#1Anna M. Varghese (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 17
#2Dana Backlund Cardin (Vandy: Vanderbilt University)H-Index: 12
Last. Leonard Saltz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 105
view all 9 authors...
Purpose: This two-part phase Ib trial determined the maximum tolerated dose (MTD) of the combination of trifluridine/tipiracil (FTD/TPI) and irinotecan in patients with advanced gastrointestinal tumors, and evaluated the safety, pharmacokinetics, and antitumor activity of the FTD/TPI, irinotecan, and bevacizumab triplet combination in previously treated metastatic colorectal cancer (mCRC). Experimental Design: Dose escalation (3+3 design) in advanced gastrointestinal tumors was followed by expan...
#2Pamela L. Kunz (Stanford University)H-Index: 32
Last. Ebrahim DelpassandH-Index: 24
view all 46 authors...
To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate. In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver...
#1David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 59
#2Steven G. DuBois (Harvard University)H-Index: 34
Last. Noah Federman (UCLA: University of California, Los Angeles)H-Index: 20
view all 29 authors...
Summary Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours. Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Som...
7 CitationsSource